Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 27, Issue 10, Pages 567-571
http://dx.doi.org/10.1155/2013/327120
Review

Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologics

Shane M Devlin,1 Brian Bressler,2 Charles N Bernstein,3 Richard N Fedorak,4 Alain Bitton,5 Harminder Singh,3 and Brian G Feagan6

1Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
2University of British Columbia, Vancouver, British Columbia, Canada
3IBD Clinical and Research Centre and Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
4Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
5Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada
6Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

Copyright © 2013 Canadian Association of Gastroenterology. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution, and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.

How to Cite this Article

Shane M Devlin, Brian Bressler, Charles N Bernstein, et al., “Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologics,” Canadian Journal of Gastroenterology, vol. 27, no. 10, pp. 567-571, 2013. https://doi.org/10.1155/2013/327120.